secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001232524-24-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma FY23 net income $414.8M vs loss; guides FY24 rev $4.0-4.2B
----------------------------------------------------------------------

- Total revenue $3.84B in 2023, up 5% YoY; Q4 revenue $1.01B, up 4% YoY.
- GAAP EPS $6.10; non-GAAP adjusted EPS $18.29, vs. $13.20 in 2022.
- Key growth drivers: Xywav +33%, Epidiolex +15%, Rylaze +40% in 2023.
- 2024 guidance: revenue $4.0-4.2B, non-GAAP adjusted EPS $18.15-19.35.
- Oncology revenue surpassed $1B in 2023; $161M remains for share buybacks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252424000014/0001232524-24-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252424000014/jazz-20240228.htm
  HTML page:      https://secwatch.observer/filing/0001232524-24-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer